리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 373 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 현기증 치료 시장은 2030년까지 23억 달러에 도달
2024년에 19억 달러로 추정되는 세계의 현기증 치료 시장은 분석 기간인 2024-2030년에 CAGR 3.2%로 성장하며, 2030년에는 23억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 양성발작성두위현훈은 CAGR 2.8%를 기록하며, 분석 기간 종료까지 9억 9,910만 달러에 달할 것으로 예측됩니다. 미로염 부문의 성장률은 분석 기간 중 CAGR 2.9%로 추정됩니다.
미국 시장은 5억 840만 달러로 추정, 중국은 CAGR 6.0%로 성장 예측
미국의 현기증 치료 시장은 2024년에 5억 840만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 4억 4,360만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.3%와 2.5%로 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.
세계의 현기증 치료 시장 - 주요 동향과 촉진요인 정리
어지럼증의 주요 원인과 효과적인 치료가 중요한 이유는 무엇인가?
어지럼증은 회전이나 움직임에 대한 잘못된 감각을 특징으로 하는 증상으로, 다양한 건강 문제의 기초 증상으로 흔히 나타납니다. 양성 발작성 두위 현기증(BPPV), 메니에르병, 전정신경염, 미로염 등이 가장 흔한 원인입니다. 어지럼증은 종종 생명을 위협하지는 않지만 어지럼증, 평형감각 문제, 메스꺼움 등을 유발하여 환자의 삶의 질에 심각한 영향을 미칠 수 있습니다. 전 세계 인구의 고령화에 따라 노인들은 전정 장애에 걸리기 쉬워 효과적인 어지럼증 치료에 대한 수요가 급증하고 있습니다.
어지럼증 치료법은 다양하며, 약리학적 개입과 비약리학적 개입이 있습니다. 항히스타민제, 항콜린제, 벤조디아제핀 등의 치료제는 일시적으로 증상을 억제하는 데 도움이 되지만, 전정재활치료(VRT)는 어지럼증 감소와 평형감각 개선을 목적으로 하는 물리치료의 일종으로 주요한 치료법으로 인식되고 있습니다. 최근 발전은 어지럼증의 근본적인 원인을 해결하는 것을 목표로 하는 보다 표적화된 개입에 초점을 맞추었습니다. 예를 들어 BPPV에 대한 입자 재배치 기술의 사용, 메니에르병에 대한 고막내 주사 등이 있습니다. 어지럼증 관련 질환에 대한 개인의 감수성을 파악하기 위한 유전자 검사 등 맞춤형 의료에 대한 관심이 높아지고 있는 것도 치료 전략의 새로운 동향입니다.
진단 기술의 발전이 어지럼증 관리를 어떻게 강화하고 있는가?
최근 진단 분야의 기술 발전으로 어지럼증 관리가 크게 향상되었습니다. MRI, CT 스캔과 같은 영상 진단 기술의 발전으로 의료진은 어지럼증을 유발할 수 있는 구조적 이상을 보다 정확하게 파악할 수 있게 되었습니다. 또한 전자 안진계(ENG)와 비디오 안진계(VNG)를 사용하여 안구 운동을 측정하고 전정 기능을 평가하는 것은 표준 진단 툴이 되었습니다. 이러한 기술은 임상의가 어지럼증의 정확한 원인을 파악하고 가장 효과적인 치료법을 추천할 수 있도록 도와줍니다.
어지럼증 진단과 모니터링을 위해 웨어러블 기술과 모바일 헬스 앱을 통합하는 움직임도 활발해지고 있습니다. 머리의 움직임, 심박수, 평형 기능을 실시간으로 추적하는 장치는 지속적인 데이터를 제공하여 증상과 경과를 모니터링하는 데 사용할 수 있습니다. 이러한 기술 혁신은 더 나은 발견을 가능하게 할 뿐만 아니라, 환자가 집에서 지속적으로 증상을 관리할 수 있는 편의성을 제공합니다. 예를 들어 환자에게 VRT를 위한 운동을 지도하도록 설계된 모바일 앱은 특히 재발성 또는 만성 어지럼증 환자의 치료 순응도 및 전반적인 결과를 개선하고 있습니다.
어지럼증 치료 수요를 주도하는 환자층은?
노인 인구는 어지럼증 치료 수요를 주도하는 주요인구 집단입니다. BPPV, 메니에르병, 전정기능장애 등 노화와 관련된 질환이 증가함에 따라 노인들이 어지럼증 치료를 찾는 빈도가 높아지고 있습니다. 낙상 위험과 운동 능력에 미치는 큰 영향을 고려할 때, 이러한 그룹에서 균형 유지와 어지럼증 관련 증상에 대한 대처는 매우 중요합니다. 또한 장수하는 인구가 증가함에 따라 전정 장애의 장기적인 관리에 대한 요구가 증가하고 있으며, 이는 시장 확대에 기여하고 있습니다.
젊은 층, 특히 전정 편두통이나 두부 외상으로 인한 평형감각 장애를 가진 사람들도 치료를 받고 있습니다. 어지럼증의 조기 진단 및 치료의 중요성에 대한 인식이 높아짐에 따라 의료 시스템은 이러한 젊은 환자의 요구를 충족시키기 위해 치료 제공을 확대하고 있습니다. 특히 도시 지역에서는 스트레스와 관련된 어지럼증과 불안으로 인한 증상 증가가 이러한 수요를 더욱 부추기고 있습니다. 현재 어지럼증을 유발하는 질환에 대한 이해의 폭이 넓어짐에 따라 의료 서비스 프로바이더는 개인의 필요에 따라 치료법을 적용하고 있으며, 치료 접근 방식 측면에서 시장은 더욱 다양해지고 있습니다.
세계 어지럼증 치료제 시장 성장 촉진요인은?
현기증 치료 시장의 성장은 전 세계 인구의 고령화, 전정 장애에 대한 인식 개선, 치료 옵션의 지속적인 발전 등 여러 가지 요인에 기인합니다. 의료 서비스 프로바이더들이 환자 중심의 접근 방식을 채택하고, 개인화된 치료, 향상된 진단 기술, 새로운 치료법의 가용성이 계속 확대되고 있습니다. 시장 개발을 위해 연구개발에 대한 투자도 증가하고 있으며, 신약 제제나 저침습 수술이 개발되고 있으며, 부작용이 적고 더 나은 치료 효과를 기대할 수 있습니다.
원격의료의 부상은 시장 성장을 더욱 촉진하고 있습니다. 환자들은 이제 원격 진료를 제공하고, 치료 진행 상황을 모니터링하고, 그에 따라 치료 계획을 조정할 수 있는 전문의에게 더 쉽게 접근할 수 있게 되었습니다. 또한 VR 운동에 가상현실(VR)과 증강현실(AR)을 통합하여 환자의 참여도를 높이고 치료를 더욱 친숙하게 만들어 수요를 더욱 촉진하고 있습니다. 정부, 보험사, 민간 의료 서비스 프로바이더들은 종합적인 어지럼증 치료 계획의 필요성을 인식하고 있으며, 특히 첨단화된 의료 시스템을 갖춘 선진국에서 세계 시장 개발을 촉진할 것으로 예측됩니다.
부문
유형(양성발작성두위현훈, 미로염, 전정 신경염, 메니에르신드롬병); 치료(항콜린제 치료, 항히스타민제 치료, 벤조디아제핀약 치료, 기타 치료); 최종사용자(병원 최종사용자, 진료소 최종사용자, 기타 최종사용자)
조사 대상 기업의 예
Abbott Laboratories
AdvaCare Pharma
Amneal Pharmaceuticals LLC
AstraZeneca
AstraZeneca(Actelion subsidiary) 1
Auris Medical(Auris Medical Holding AG)
DizzyFIX
Eli Lilly and Company
Epic Pharma, LLC
F. Hoffmann-La Roche Ltd(Roche)
GlaxoSmithKline(GSK)
Intas Pharmaceuticals Ltd
Lupin Limited
Medtronic
Mylan/Viatris Inc.
Novartis AG
Otolith Labs
Pfizer Inc.
Prestige Consumer Healthcare Inc.
Sanofi
AI 통합
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Vertigo Treatment Market to Reach US$2.3 Billion by 2030
The global market for Vertigo Treatment estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Benign Paroxysmal Positional Vertigo, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$999.1 Million by the end of the analysis period. Growth in the Labyrinthitis segment is estimated at 2.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$508.4 Million While China is Forecast to Grow at 6.0% CAGR
The Vertigo Treatment market in the U.S. is estimated at US$508.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$443.6 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.
Global Vertigo Treatment Market - Key Trends & Drivers Summarized
What Are the Main Causes of Vertigo and Why Is Effective Treatment So Critical?
Vertigo, a condition characterized by a false sense of spinning or movement, is a common symptom of a range of underlying health issues. It affects millions globally, with benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular neuritis, and labyrinthitis being some of the most frequent causes. While often not life-threatening, vertigo can severely impact a patient's quality of life, causing dizziness, balance issues, and nausea. As the global population ages, with elderly individuals more susceptible to vestibular disorders, the demand for effective vertigo treatments has surged.
The treatment landscape for vertigo is diverse, including both pharmacological and non-pharmacological interventions. Medications such as antihistamines, anticholinergics, and benzodiazepines help manage symptoms temporarily, while vestibular rehabilitation therapy (VRT), a form of physical therapy designed to reduce dizziness and improve balance, is increasingly recognized as a primary treatment. Recent advancements have focused on more targeted interventions that aim to address the underlying causes of vertigo, such as the use of particle repositioning techniques for BPPV and intratympanic injections for Meniere’s disease. The growing focus on personalized care, such as genetic testing to understand individual susceptibility to vertigo-related conditions, is another emerging trend in treatment strategies.
How Are Technological Advancements in Diagnosis Enhancing Vertigo Management?
Recent technological advancements in diagnostics are significantly enhancing the management of vertigo. Advances in imaging technologies, including MRI and CT scans, have allowed healthcare professionals to better identify structural abnormalities that could be causing vertigo. Additionally, the use of electronystagmography (ENG) and videonystagmography (VNG) to measure eye movements and assess vestibular function has become a standard diagnostic tool. These technologies help clinicians determine the exact cause of vertigo, enabling them to recommend the most effective treatments.
The integration of wearable technology and mobile health apps for vertigo diagnosis and monitoring is also gaining traction. Devices that track head movement, heart rate, and balance function in real-time provide continuous data, which can be used to monitor symptoms and progress over time. These innovations not only enable better detection but also offer patients the convenience of ongoing symptom management at home. For example, mobile apps designed to guide patients through exercises for VRT are improving treatment adherence and overall outcomes, especially for patients with recurrent or chronic vertigo.
Which Patient Demographics Are Driving Demand for Vertigo Treatments?
The elderly population is the primary demographic driving the demand for vertigo treatments. As age-related conditions such as BPPV, Meniere’s disease, and vestibular dysfunction increase, older adults are more frequently seeking treatment for vertigo. Given the risk of falls and the significant impact on mobility, maintaining balance and addressing vertigo-related symptoms in this group is crucial. Additionally, as more people are living longer, there is a growing need for long-term management of vestibular disorders, which is contributing to the market's expansion.
Younger populations, particularly those with vestibular migraines or balance disorders due to head injuries, are also seeking treatment. As awareness of the importance of early diagnosis and treatment of vertigo grows, healthcare systems are expanding their care offerings to meet the needs of these younger patients. The rise of stress-related vertigo and anxiety-induced symptoms, especially in urban settings, is further contributing to this demand. With a broader range of conditions now understood to cause vertigo, healthcare providers are tailoring treatments to individual needs, making the market more diverse in terms of treatment approaches.
What Are the Key Drivers of Growth in the Global Vertigo Treatment Market?
The growth in the vertigo treatment market is driven by several factors, including an aging global population, increased awareness of vestibular disorders, and ongoing advancements in treatment options. As healthcare providers adopt a more patient-centered approach, the availability of personalized treatments, improved diagnostic techniques, and novel therapies continues to grow. The market is also seeing increased investment in research and development, with new drug formulations and minimally invasive procedures in the pipeline that promise better outcomes with fewer side effects.
The rise of telemedicine is further enhancing the market's growth. Patients now have greater access to specialists who can provide remote consultations, monitor treatment progress, and adjust care plans accordingly. Additionally, the integration of virtual reality (VR) and augmented reality (AR) in VRT exercises is improving patient engagement and making therapy more accessible, further driving demand. Governments, insurance companies, and private healthcare providers are recognizing the need for comprehensive vertigo treatment plans, which is expected to fuel market expansion globally, especially in developed countries with advanced healthcare systems.
SCOPE OF STUDY:
The report analyzes the Vertigo Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis, Meniere's Disease); Treatment (Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment, Other Treatments); End-User (Hospitals End-User, Clinics End-User, Other End-Users)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
Abbott Laboratories
AdvaCare Pharma
Amneal Pharmaceuticals LLC
AstraZeneca
AstraZeneca (Actelion subsidiary)1
Auris Medical (Auris Medical Holding AG)
DizzyFIX
Eli Lilly and Company
Epic Pharma, LLC
F. Hoffmann-La Roche Ltd (Roche)
GlaxoSmithKline (GSK)
Intas Pharmaceuticals Ltd
Lupin Limited
Medtronic
Mylan/Viatris Inc.
Novartis AG
Otolith Labs
Pfizer Inc.
Prestige Consumer Healthcare Inc.
Sanofi
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Vertigo Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Vestibular Disorders Throws the Spotlight on Demand for Vertigo Treatment Options
Aging Population and Associated Balance Disorders Spur Growth in Pharmacologic and Non-Pharmacologic Therapies
Increasing Diagnosis of Benign Paroxysmal Positional Vertigo (BPPV) Expands Addressable Market for Targeted Treatments
Advancements in Vestibular Rehabilitation Therapy Strengthen the Business Case for Physical and Digital Therapeutic Programs
Growing Use of Antihistamines and Vestibular Suppressants Drives Demand for Prescription-Based Vertigo Medications
Rise in Neurological Complications Accelerate Interest in Vertigo and Dizziness-Related Treatments
Rising Awareness and Patient Education Initiatives Propel Early Diagnosis and Timely Intervention
Integration of Virtual Reality in Balance Training Creates Tailwinds for Non-Invasive Treatment Modalities
Wearable Motion and Balance Sensors Enhance Monitoring and Personalization in Vertigo Management
Innovation in Multimodal Treatment Protocols Improves Outcomes in Chronic and Recurrent Vertigo Cases
Telehealth and App-Based Tools Facilitate Remote Vestibular Therapy and Medication Management
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Vertigo Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Vertigo Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Vertigo Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Vertigo Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Benign Paroxysmal Positional Vertigo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Benign Paroxysmal Positional Vertigo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Benign Paroxysmal Positional Vertigo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Labyrinthitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Labyrinthitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Labyrinthitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Vestibular Neuronitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Vestibular Neuronitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Vestibular Neuronitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Meniere's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Meniere's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Meniere's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Anticholinergics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Anticholinergics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Anticholinergics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Antihistamines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Antihistamines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Antihistamines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Benzodiazepines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Benzodiazepines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Benzodiazepines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: USA 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: USA 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: USA 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: Canada 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: Canada 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: Canada 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
JAPAN
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: Japan 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: Japan 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: Japan 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
CHINA
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: China 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: China 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: China 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
EUROPE
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Vertigo Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Vertigo Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: Europe 16-Year Perspective for Vertigo Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: Europe 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: Europe 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: Europe 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
FRANCE
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: France 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: France 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: France 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
GERMANY
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Germany 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: Germany 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: Germany 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: Italy 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: Italy 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: Italy 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
UNITED KINGDOM
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: UK 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: UK 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: UK 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: Spain 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: Spain 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Spain 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Russia 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Russia 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Russia 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: Rest of Europe 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: Rest of Europe 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Vertigo Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Vertigo Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
AUSTRALIA
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: Australia 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: Australia 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: Australia 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
INDIA
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 170: India Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: India 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: India 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: India 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: South Korea 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: South Korea 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: South Korea 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
LATIN AMERICA
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Vertigo Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Vertigo Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Latin America 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 211: Argentina 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 214: Argentina 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 217: Argentina 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 220: Brazil 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 223: Brazil 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 226: Brazil 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 229: Mexico 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 232: Mexico 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 235: Mexico 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 241: Rest of Latin America 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 244: Rest of Latin America 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
MIDDLE EAST
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Vertigo Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Vertigo Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 253: Middle East 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 259: Iran 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 262: Iran 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 265: Iran 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 268: Israel 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 271: Israel 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 274: Israel 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 280: Saudi Arabia 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 283: Saudi Arabia 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 286: UAE 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 289: UAE 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 292: UAE 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 298: Rest of Middle East 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 301: Rest of Middle East 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030
AFRICA
Vertigo Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Vertigo Treatment by Type - Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 304: Africa 16-Year Perspective for Vertigo Treatment by Type - Percentage Breakdown of Value Sales for Benign Paroxysmal Positional Vertigo, Labyrinthitis, Vestibular Neuronitis and Meniere's Disease for the Years 2014, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Vertigo Treatment by End-user - Clinics End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 307: Africa 16-Year Perspective for Vertigo Treatment by End-user - Percentage Breakdown of Value Sales for Clinics End-User, Other End-Users and Hospitals End-User for the Years 2014, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Vertigo Treatment by Treatment - Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 310: Africa 16-Year Perspective for Vertigo Treatment by Treatment - Percentage Breakdown of Value Sales for Anticholinergics Treatment, Antihistamines Treatment, Benzodiazepines Treatment and Other Treatments for the Years 2014, 2025 & 2030